FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Metastatic Breast Cancer
Personal Story : Running marathons with metastatic breast cancer? Yes!
Most relevant for: Women with metastatic breast cancer
Runner’s World Magazine featured Sarah Smith, a metastatic breast cancer patient who runs marathons and ultra-marathons. By telling her story, Sarah wants to encourage people to stay active, despite the challenges that life may bring. (10/13/19)
Read More
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Study : Inherited mutations in metastatic breast cancer patients
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People with metastatic breast cancer
Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)
Read More
Guideline : FDA issues warning on CDK inhibitors
Most relevant for: People currently taking a CDK inhibitor
The U.S. Food and Drug Administration issued a safety alert for CDK inhibitors, including Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib). (9/24/19)
Read More
Study : Supportive care can improve quality of life for people with metastatic breast cancer
Most relevant for: People diagnosed with metastatic breast cancer
Metastatic breast cancer patients have unique needs for treatment and care. Connecting patients to appropriate support services and palliative care is an area of need in health care. A recent study reported improvement in metastatic breast cancer patient quality of life and wellness with an intervention program called the Supportive, Education and Advocacy (MBC-SEA) program. (8/21/19)
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : CDK inhibitors may increase survival for ER-positive metastatic breast cancer patients
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with metastatic, hormone-positive, Her2-negative breast cancer
The phase III MONALEESA-7 study is a clinical trial looking at the effect of a type of treatment known as a CDK4/6 inhibitor in pre- or perimenopausal women with hormone receptor–positive advanced breast cancer. (7/22/19)
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : LGBTQ patients recommend improvements for their cancer care
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: LGBTQ cancer patients and their healthcare providers.
Very little research has focused on the cancer care experiences of lesbian, gay, bisexual, transgender and queer (LGBTQ) people. This study looks at recommendations from the LGBTQ community for improving their cancer care. (6/20/19)
Read More
Guideline : FDA approves an immunotherapy treatment for some patients with triple-negative breast cancer
Most relevant for: People with metastatic, triple-negative breast cancer
THIS INFORMATION HAS BEEN UPDATED: In August 2021 Roche voluntarily withdrew their FDA accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1.
The FDA approved the use of the immunotherapy drug atezolizumab (Tecentriq) in combination with the chemotherapy agent nab-paclitaxel (Abraxane) for certain patients with advanced triple-negative breast cancer. (5/26/19)
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Smart drug shows promising results for treatment of metastatic triple-negative breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with metastatic, triple-negative breast cancer
THIS INFORMATION HAS BEEN UPDATED on 04/27/20: Based on the results from the study reviewed in this XRAY, the U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hizy (Trodelvy), as a treatment for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.
We report results of an early-stage clinical trial of a new class of drugs for metastatic triple-negative breast cancer (TNBC). IMMU-132 is a combination of two different molecules: an antibody that targets certain types of cancer and delivers a chemotherapy drug that can kill cancer cells. This study looks at whether IMMU-132 is safe and effective for treating metastatic TNBC. (4/16/19)
Read More
Relevance: Medium-High
Research Timeline: Post Approval
Guideline : Breast surgeons recommend genetic testing for all breast cancer patients
Relevance: Medium-High
Research Timeline: Post Approval
Most relevant for: Anyone diagnosed with breast cancer
The American Society of Breast Surgeons published statement on genetic testing for hereditary breast cancer on February 10, 2019. It includes recommendations about who should be tested. Among these is the recommendation that all breast cancer patients get genetic testing, as well as women who do not have breast cancer but fit the National Comprehensive Cancer Network (NCCN) guidelines. (3/25/19)
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Prevalence of BRCA founder mutations in Bahamian women
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Bahamanian women
The Bahamas has the highest known frequency of BRCA mutations among people diagnosed with breast cancer. This study reviewed whether population-based BRCA testing (testing everyone regardless of family or personal history of cancer) would be an effective approach for finding mutation carriers in the Bahamas. (3/4/19)
Read More
Search XRAY studies and Articles
This Portal Sponsored By:
